Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan and Fludarabine Conditioning for Unrelated Donor SCT
NCT00516152Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Nov 2002
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan and fludarabine in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 6 more, sponsored by University of California, San Francisco. Primary endpoints: Transplant Related Mortality at 100 days and Overall Survival at 1 year. Started Nov 2002; status: completed.
02
Drugs
busulfanfludarabine
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)aplastic anemia
Beyond the preview
Go deeper on NCT00516152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516152.